kx2-361
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02326441)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SRCINHIBITOR
SRC inhibitor
- Tyrosine-protein kinase Fyn (FYN) ↗
- Proto-oncogene tyrosine-protein kinase Src (SRC) ↗
- Tyrosine-protein kinase Lck (LCK) ↗
- Tyrosine-protein kinase Yes (YES1) ↗
- Tyrosine-protein kinase Blk (BLK) ↗
- Tyrosine-protein kinase HCK (HCK) ↗
- Tyrosine-protein kinase Lyn (LYN) ↗
- Tyrosine-protein kinase FRK (FRK) ↗
- Tyrosine-protein kinase Fgr (FGR) ↗
- Tyrosine-protein kinase Srms (SRMS) ↗
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Cc1ccc(-c2ccc(N3CCOCC3)cc2)cn1)NCc1cccc(F)c1- Mol. weight
- 405.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297299 ↗
Also known as
- kx2-361
- kx2-361
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02326441 | Phase 1 | Dec 1, 2014 | Athenex, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Athenex, Inc. | For profit | 1 | 1 | 1 | 2014 |
1 organizations
Page 1 / 1